Come up with a name for your new list and we'll add to it:
ViraCyte raised a round of funding on August 21, 2017. Investors include
Cancer Prevention and Research Institute of Texas.
ViraCyte is a clinical-stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe life-threatening infections. The company provides products that restore…